报价延迟最少15分钟:2025/09/05 18:00 EDT
盘后时段
|
||||
|
1.29 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.27
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.88/-0.38
|
|
企业价值
76.68M
|
| 资产负债 |
|
每股账面净值
0.29
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.99M
|
|
每股收益
1.73
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/05 18:00 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy. |
